18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA ExpressionPrimary· through study completion, an average of 2 and a half years
Survival will be assessed though different consultations (in person or by telemedicine). Patient follow-up was conducted over 2 years and 6 months, consisting of periodic telephone visits at 1 month, 3 months, 6 months, 1 year, 2 years, and 2½ years (until the end of the study), respectively, collecting the following data: history and ECOG score.
Group
Value
95% CI
Patients With Solid Pancreatic Masses
8.3
± 7.526
Adverse events — posted to ClinicalTrials.gov
Time frame: 2 and a half years.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Patients With Solid Pancreatic Masses
Serious: 37/41 (90%)
Deaths: 41/41
Serious adverse events (1 terms)
Reaction
System
Patients With Solid Pancre…
death
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic adenocarcinoma still represents one of the "hot-topics" worldwide. Endoscopic ultrasonography was a breakthrough, bringing us closer to personalized treatment by getting histopathological samples through fine-needle-aspiration or fine-needle-biopsy. These samples can be analyzed and offer the possibility to detect a micro-RNA profile.
Micro-RNAs are small non-coding RNA molecules that interfere in genic expression. Many studies focused on seric microRNA profile, though there are many implications in tissue micro-RNA profile, thus overexpression or under expression of these molecules might help us not only understand different cellular processes, but also interfere in personalized medicine in the future.
The investigators propose a prospective, multicenter, randomized, cohort study on 60 patients with solid pancreatic masses to evaluate tissue microRNA profile obtained by EUS-FNA.
The primary hypothesis is to correlate the microRNA tissular expression in pancreatic adenocarcinoma with tumor aggressive behavior, survival and response to treatment.
The samples will be obtained from the participants during endoscopic ultrasonography, through fine needle aspiration, after consent was given to be a part of the study prior to the intervention. The probe will be preserved in a special recipient that stabilizes RNA and inhibits RNA-lazes, thus preventing RNA degradation by endogenous ribonucleases.
The analysis of miRNA profile will be made using qRT-PCR array method, by miScript II RT Kit, miScript SYBR Green PCR Kit și miScript miRNA PCR Array Human Cancer Pathway Finder (MIHS-102Z) (Qiagen, GmbH). Thus a kit containing a number of 84 miRNAs will be analysed in every participant.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
· Phase 2
· recruiting
NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
· Phase 1, PHASE2
· recruiting
NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P
· NA
· recruiting
NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE
· Phase 1
· recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
· Phase 1
· recruiting
Other Carol Davila University of Medicine and Pharmacy trials
Trials by the same sponsor.
NCT07442552 — Perioperative Sepsis. An Epigenetic Perspective
· recruiting
NCT06683326 — Smart-gloves Hand Motion Tracking for Live Endoscopic Submucosal Dissection Training
· NA
· not yet recruiting
NCT06679972 — Impact of Intrahepatic Cholestasis of Pregnancy on Neonatal Respiratory Outcomes
· enrolling by invitation
NCT06218537 — The Role of oAncreatic Enzyme ReplAcement Therapy (PERT) on Mucosal Visibility Before Upper GI Endoscopy
· NA
· completed
NCT06224023 — Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carol Davila University of Medicine and Pharmacy
Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04765410.